Considering that liver and gastric cancers are both major diseases that pose a serious threat to people’s health, and there are a large numbers of cancer patients with abnormal expressions of c-Met or NTRK, or simultaneous of them, we believe that as a multi-target kinase inhibitor, 1D228 will play an significant role in the treatment of the aforementioned cancer patients after it is approved. This evidence concerns the gene MET and gastric cancer.